Sanofi SA posted strong gains in both sales and operating profit in the first quarter boosted by medicine stockpiling during the COVID-19 pandemic in Europe. The quarterly result also featured a more than doubling of sales for the immunology drug Dupixent, which was co-developed with Regeneron Pharmaceuticals Inc.
